Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by 4 Cycles XELOX Pre- a Delayed TME Compared With 6 Cycles XELOX post-a Regular Timing TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized, Open-Label Trial

Trial Profile

Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by 4 Cycles XELOX Pre- a Delayed TME Compared With 6 Cycles XELOX post-a Regular Timing TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized, Open-Label Trial

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Fluorouracil
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Acronyms EXPLORE
  • Most Recent Events

    • 02 Aug 2017 The protocol has been amended to include 6 Cycles XELOX post- TME instead of 8 cycles.
    • 02 Aug 2017 Planned number of patients changed from 610 to 508.
    • 02 Aug 2017 Planned initiation date changed from 1 Apr 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top